{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:27:25Z","timestamp":1767148045154,"version":"build-2238731810"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jneuroim.2008.05.023","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T20:17:22Z","timestamp":1216239442000},"page":"128-135","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent"],"prefix":"10.1016","volume":"201-202","author":[{"given":"Renuka T.R.","family":"Menon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Feferman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revital","family":"Aricha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam C.","family":"Souroujon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2008.05.023_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1043-6618(03)00002-1","article-title":"The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat","volume":"47","author":"Abdel-Salam","year":"2003","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcp.2004.09.012","article-title":"Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells","volume":"69","author":"Ahlstrom","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","article-title":"Immunosuppressive drugs: the first 50\u00a0years and a glance forward","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00007890-199107000-00027","article-title":"Evidence that glucocorticosteroid-mediated immunosuppressive effects do not involve altering second messenger function","volume":"52","author":"Almawi","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib5","first-page":"595","article-title":"Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory\/immunomodulatory drug potentially useful in some rheumatic diseases","volume":"22","author":"Anaya","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1096\/fj.05-4909fje","article-title":"Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor","volume":"20","author":"Aricha","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-6576.2004.00547.x","article-title":"Pentoxifylline attenuates the increase in whole blood viscosity after transfusion","volume":"49","author":"Bacher","year":"2005","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2004.06.008","article-title":"PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease","volume":"25","author":"Banner","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jlb.40.6.747","article-title":"Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells","volume":"40","author":"Bessler","year":"1986","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib10","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.4049\/jimmunol.161.12.7015","article-title":"Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline","volume":"161","author":"Bright","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0192-0561(97)85556-7","article-title":"Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline","volume":"18","author":"D'Hellencourt","year":"1996","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1027362629161","article-title":"Different regulatory effects of pentoxifylline on human T cell activation pathways","volume":"17","author":"Dong","year":"1997","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib13","first-page":"2382","article-title":"Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis","volume":"30","author":"Galindo-Rodriguez","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s004320100262","article-title":"Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline","volume":"127","author":"Gude","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.300.2.559","article-title":"Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells","volume":"300","author":"Haddad","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.172.1.391","article-title":"Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin\/tumor necrosis factor synthesis at separate points in the signaling pathway","volume":"172","author":"Han","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI8121","article-title":"Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment","volume":"104","author":"Im","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.4049\/jimmunol.133.2.784","article-title":"Glucocorticoid inhibition of lymphokine secretion by alloreactive T lymphocyte clones","volume":"133","author":"Kelso","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/cimm.1993.1134","article-title":"Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone","volume":"149","author":"Kunicka","year":"1993","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s004150050135","article-title":"Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients","volume":"244","author":"Lindner","year":"1997","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.271.1.27","article-title":"Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus","volume":"271","author":"MacDonald","year":"1994","journal-title":"Jama"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2004.04.010","article-title":"Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment","volume":"152","author":"Maiti","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib23","first-page":"625","article-title":"An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis","volume":"22","author":"Maksymowych","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib24","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1172\/JCI107096","article-title":"An effect of dexamethasone on adenosine 3\u2032,5\u2032-monophosphate content and adenosine 3\u2032,5\u2032-monophosphate phosphodiesterase activity of cultured hepatoma cells","volume":"51","author":"Manganiello","year":"1972","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0162-3109(00)00249-6","article-title":"Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages","volume":"49","author":"Marcinkiewicz","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-5728(00)00385-4","article-title":"Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR","volume":"111","author":"Poussin","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.510260210","article-title":"Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells","volume":"26","author":"Preaux","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0378-5173(00)00544-5","article-title":"Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: in vitro immunosuppressive effects on rat blood and spleen lymphocytes","volume":"207","author":"Rensberger","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-5728(95)00176-X","article-title":"Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis","volume":"64","author":"Rieckmann","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mus.1220","article-title":"Steroid treatment for myasthenia gravis: steroids are overutilized","volume":"25","author":"Rivner","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.05.023_bib32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/eji.1830230802","article-title":"Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats","volume":"23","author":"Rott","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00000198","article-title":"Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis","volume":"49","author":"Silva","year":"2000","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib35","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/ndt\/15.10.1535","article-title":"Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts","volume":"15","author":"Strutz","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1253\/circj.66.499","article-title":"Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis","volume":"66","author":"Takehana","year":"2002","journal-title":"Circ. J."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib37","first-page":"1313","article-title":"Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors","volume":"272","author":"Verghese","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0014-2999(02)01625-4","article-title":"Timing of pentoxifylline treatment determines its protective effect on diabetes development in the Bio Breeding rat","volume":"445","author":"Visser","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.05.023_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0165-5728(00)00411-2","article-title":"Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR","volume":"113","author":"Zhang","year":"2001","journal-title":"J. Neuroimmunol."}],"updated-by":[{"DOI":"10.1016\/j.jneuroim.2009.07.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T00:00:00Z","timestamp":1256860800000}}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T02:00:14Z","timestamp":1684461614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572808002099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":39,"alternative-id":["S0165572808002099"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.023","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}